Lymphact is a biopharmaceutical start-up focused on developing innovative personalized medical treatments.
Our products and technologies are designed to harness the power of the immune system, the target-specific cellular mechanism which evolved in vertebrates during the last 450 million years, towards a permanent elimination of pathogens. After 5 years of pioneering research and development in this field, we created a new technology platform which can generate autologous and heterologous cellular immune therapies for clinical applications – the DOT-Cells®.
DOT-Cells® can target not only cancer and virus-infected cells, but also chemotherapy-resistant cancer stem cells and viral reservoirs, believed to cause disease recurrence. An improved anti-tumour function and the absence of severe associated side-effects are distinctive and unique features of our therapeutic approach.
Chairmand and CEO
Diogo R. Anjos